Ribonucleic
acid
(RNA)
plays
a
pivotal
role
in
gene
regulation
and
protein
biosynthesis.
Interfering
the
physiological
function
of
key
RNAs
to
induce
cell
apoptosis
holds
great
promise
for
cancer
treatment.
Many
RNA-targeted
anti-cancer
strategies
have
emerged
continuously.
Among
them,
RNA
interference
(RNAi)
has
been
recognized
as
promising
therapeutic
modality
various
disease
treatments.
Nevertheless,
primary
obstacle
siRNA
delivery-escaping
endosome
crossing
plasma
membrane
severely
impedes
its
potential.
Thus
far,
variety
nanosystems
well
carrier-free
bioconjugation
delivery
developed
employed
enhance
drug
anti-tumor
efficiency.
Besides,
use
small
molecules
target
specific
structures
disrupt
their
function,
along
with
covalent
modification
RNA,
also
drawn
tremendous
attention
recently
owing
high
efficacy.
In
this
review,
we
will
provide
an
overview
recent
progress
therapy
including
strategies,
RNA-targeting
molecules,
newly
modification.
Finally,
challenges
future
perspectives
faced
research
field
be
discussed.
Bioengineering,
Год журнала:
2023,
Номер
10(7), С. 760 - 760
Опубликована: Июнь 25, 2023
Nano-oncology
is
a
branch
of
biomedical
research
and
engineering
that
focuses
on
using
nanotechnology
in
cancer
diagnosis
treatment.
Nanomaterials
are
extensively
employed
the
field
oncology
because
their
minute
size
ultra-specificity.
A
wide
range
nanocarriers,
such
as
dendrimers,
micelles,
PEGylated
liposomes,
polymeric
nanoparticles
used
to
facilitate
efficient
transport
anti-cancer
drugs
at
target
tumor
site.
Real-time
labeling
monitoring
cells
quantum
dots
essential
for
determining
level
therapy
needed
The
drug
targeted
site
either
by
passive
or
active
means.
Passive
targeting
makes
use
microenvironment
enhanced
permeability
retention
effect,
while
involves
ligand-coated
nanoparticles.
Nanotechnology
being
diagnose
early
stage
detecting
cancer-specific
biomarkers
imaging.
implication
employs
photoinduced
nanosensitizers,
reverse
multidrug
resistance,
enabling
delivery
CRISPR/Cas9
RNA
molecules
therapeutic
applications.
However,
despite
recent
advancements
nano-oncology,
there
need
delve
deeper
into
domain
designing
applying
improved
diagnostics.
Bioconjugate Chemistry,
Год журнала:
2023,
Номер
34(7), С. 1177 - 1197
Опубликована: Июль 11, 2023
Short
interfering
RNAs
(siRNA)
are
a
powerful
class
of
genetic
medicines
whose
clinical
translation
can
be
hindered
by
their
suboptimal
delivery
properties
in
vivo.
Here,
we
provide
clinically
focused
overview
that
summarizes
ongoing
siRNA
trials
from
the
perspective
innovations
nonviral
strategies.
More
specifically,
our
review
begins
highlighting
barriers
and
physiochemical
make
it
challenging
to
deliver
We
then
commentary
on
specific
strategies,
including
sequence
modification,
ligand
conjugation,
nanoparticle
exosomal
packaging,
each
which
used
control
therapies
living
systems.
Last,
summary
table
also
highlights
indication
use,
target,
National
Clinical
Trial
(NCT)
number
associated
with
entry.
In
writing
this
review,
work
aims
highlight
key
challenges
strategies
for
effective
vivo,
while
simultaneously
summarizing
information
therapy
humans.
ACS Nano,
Год журнала:
2024,
Номер
18(17), С. 10979 - 11024
Опубликована: Апрель 18, 2024
Nanomaterials
have
attractive
physicochemical
properties.
A
variety
of
nanomaterials
such
as
inorganic,
lipid,
polymers,
and
protein
nanoparticles
been
widely
developed
for
nanomedicine
via
chemical
conjugation
or
physical
encapsulation
bioactive
molecules.
Superior
to
traditional
drugs,
nanomedicines
offer
high
biocompatibility,
good
water
solubility,
long
blood
circulation
times,
tumor-targeting
Capitalizing
on
this,
several
nanoformulations
already
clinically
approved
many
others
are
currently
being
studied
in
clinical
trials.
Despite
their
undoubtful
success,
the
molecular
mechanism
action
vast
majority
remains
poorly
understood.
To
tackle
this
limitation,
herein,
review
critically
discusses
strategy
applying
multiomics
analysis
study
nanomedicines,
named
nanomedomics,
including
advantages,
applications,
future
directions.
comprehensive
understanding
could
provide
valuable
insight
therefore
foster
development
translation
nanomedicines.
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2024,
Номер
43(1)
Опубликована: Авг. 30, 2024
Camptothecin
(CPT)
is
one
of
the
frequently
used
small
chemotherapy
drugs
for
treating
hepatocellular
carcinoma
(HCC),
but
its
clinical
application
limited
due
to
severe
toxicities
and
acquired
resistance.
Combined
chemo-gene
therapy
has
been
reported
be
an
effective
strategy
counteracting
drug
resistance
while
sensitizing
cancer
cells
cytotoxic
agents.
Thus,
we
hypothesized
that
combining
CPT
with
miR-145
could
synergistically
suppress
tumor
proliferation
enhance
anti-tumor
activity.
Abstract
Research
into
the
anticancer
activity
of
quantum-sized
carbon
dots
(CDs)
has
emerged
as
a
promising
avenue
in
cancer
research.
This
CDs
delves
opportunities
and
challenges
associated
with
harnessing
potential
these
nanostructures
for
combating
cancer.
Quantum-sized
dots,
owing
to
their
unique
physicochemical
properties,
exhibit
distinct
advantages
therapeutic
agents.
Opportunities
lie
tunable
size,
surface
functionalization
capabilities,
biocompatibility,
enabling
targeted
drug
delivery
imaging
cells.
However,
we
include
challenges,
comprehensive
understanding
underlying
mechanisms,
toxicity
concerns,
optimization
synthesis
methods
enhanced
efficacy.
A
succinct
summary
state
research
this
area
is
given
review,
emphasizing
exciting
possibilities
ongoing
utilizing
novel
strategy
treatment.
Advanced Drug Delivery Reviews,
Год журнала:
2023,
Номер
203, С. 115136 - 115136
Опубликована: Ноя. 7, 2023
The
limitations
inherent
in
conventional
cancer
treatment
methods
have
stimulated
recent
efforts
towards
the
design
of
safe
nanomedicines
with
high
efficacy
for
combating
through
various
promising
approaches.
A
plethora
nanoparticles
has
been
introduced
development
nanomedicines.
Among
them,
different
lipid
are
attractive
use
due
to
numerous
advantages
and
unique
opportunities,
including
biocompatibility
targeted
drug
delivery.
However,
a
comprehensive
understanding
nano-bio
interactions
is
imperative
facilitate
translation
advancements
into
clinical
practice.
In
this
contribution,
we
focus
on
lipoprotein-mimicking
nanoparticles,
which
possess
features
compositions
facilitating
transport
receptor
binding
mechanisms.
Additionally,
describe
potential
applications
siRNA
future
anticancer
Thus,
review
highlights
progress,
challenges,
opportunities
lipid-based
nanocarriers
designed
delivery
therapeutic
agents.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Ноя. 14, 2024
RNA
therapeutics,
such
as
mRNA,
siRNA,
and
CRISPR–Cas9,
present
exciting
avenues
for
treating
diverse
diseases.
However,
their
potential
is
commonly
hindered
by
vulnerability
to
degradation
poor
cellular
uptake,
requiring
effective
delivery
systems.
Lipid
nanoparticles
(LNPs)
have
emerged
a
leading
choice
in
vivo
delivery,
offering
protection
against
degradation,
enhanced
facilitation
of
endosomal
escape.
LNPs
encounter
numerous
challenges
targeted
vivo,
demanding
advanced
particle
engineering,
surface
functionalization
with
targeting
ligands,
profound
comprehension
the
biological
milieu
which
they
function.
This
review
explores
structural
physicochemical
characteristics
LNPs,
in-vivo
fate,
customization
therapeutics.
We
highlight
quality-by-design
(QbD)
approach
beyond
liver,
focusing
on
biodistribution,
immunogenicity,
toxicity.
In
addition,
we
explored
current
strategies
associated
ensuring
repeated-dose
efficacy,
safety,
tissue-specific
gene
delivery.
Furthermore,
provide
insights
into
clinical
applications
various
classes
diseases
finally
prospects
